1-5 of 5
Monica Shah
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Minimal Residual Disease (MRD)-Adapted Duration of Front-Line Venetoclax and Obinutuzumab Treatment for Fit Patients with Chronic Lymphocytic Leukemia (CLL)

Lindsey Roeker, Anthony R. Mato, Andrew D. Zelenetz, Jae H. Park, Mark Blaine Geyer, Andriy Derkach, David Nemirovsky, Prioty Islam, Lorenzo Falchi, Maria Lia Palomba, Anita Kumar, Gilles Salles, Jennifer Kimberly Lue, Aaron D. Goldberg, Deborah M. Stephens, Victoria Duffy, Gail Panton, Dianna Tyznar, Colleen Dorsey, Dhara Soni, Claire Hutzler, Lauren Nogan, Alexandra Allen, Tenzin Nyima, Thu Quynh Nguyen, Monica Shah, Tamotha R Cook, Jennifer Abillar-Wright, Jamila Brutus, Carissa Laudati, Bejal Kikani, Catherine C Coombs, Michael R. Silvestrone, Christopher E. Jensen, Bita Fakhri, Meghan C. Thompson
Journal: Blood
Blood (2024) 144 (Supplement 1): 1010.
https://doi.org/10.1182/blood-2024-203807
Published: 2024
Journal Articles

Outcomes of Therapies Following Discontinuation of Non-Covalent Bruton's Tyrosine Kinase Inhibitors for Patients with Chronic Lymphocytic Leukemia and Richter Transformation: Results from an International, Multicenter Study

Meghan C. Thompson, Seema A. Bhat, Wojciech Jurczak, Krish Patel, Nirav N. Shah, Jennifer A. Woyach, Catherine C. Coombs, Toby A. Eyre, Michal Danecki, Monika Dlugosz-Danecka, Neil Bailey, Joanna M. Rhodes, Nicole Lamanna, Andrew H. Lipsky, Jeffrey Jensen, Adam Kidwell, Eytan M. Stein, Monica Shah, Jennifer R. Brown, Andriy Derkach, Anthony R. Mato, Lindsey Roeker
Journal: Blood
Blood (2024) 144 (Supplement 1): 1870.
https://doi.org/10.1182/blood-2024-194748
Published: 2024
Journal Articles

A Phase 2 Study of Minimal Residual Disease (MRD)-Adapted Front Line Venetoclax and Obinutuzumab in Fit Patients with Chronic Lymphocytic Leukemia (CLL): Effect of Obinutuzumab on Tumor Lysis Syndrome (TLS) Risk and Safety of Outpatient Venetoclax Dose Escalation

Lindsey E. Roeker, Andrew D. Zelenetz, Jae H. Park, Andriy Derkach, Mark Blaine Geyer, Prioty Islam, Lorenzo Falchi, Maria Lia Palomba, Anita Kumar, Gilles Salles, Jennifer Kimberly Lue, Aaron D. Goldberg, Bita Fakhri, Catherine C. Coombs, Victoria Falco, Gail Panton, Dianna Tyznar, Dhara Soni, Lauren Nogan, Sonia Lebowitz, Katherine Blesie, Monica Shah, Sarah Court, Christopher E. Jensen, Anthony R. Mato, Meghan C. Thompson
Journal: Blood
Blood (2023) 142 (Supplement 1): 4657.
https://doi.org/10.1182/blood-2023-181661
Published: 2023
Journal Articles

In Vitro , In Vivo , and Parallel Phase I Evidence Support the Safety and Activity of Duvelisib, a PI3K-δ,γ Inhibitor, in Combination with Romidepsin or Bortezomib in Relapsed/Refractory T-Cell Lymphoma

Alison J. Moskowitz, MD, Raphael Koch, MD, Neha Mehta-Shah, MD, Patricia Myskowski, MD, Meenal Kheterpal, MD, Ahmet Dogan, MD PhD, Theresa Davey, MPAS, Natasha Galasso, BA, Marzouk Evan, BA, Monica Shah, BA, Nivetha Ganesan, BS, Lakeisha Lubin, BS, Youn H. Kim, MD, Michael Khodadoust, MD PhD, Timothy Almazan, MD, Julia Dai, MD, Eric D. Jacobsen, MD, David M. Weinstock, MD, Steven M. Horwitz, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 819.
https://doi.org/10.1182/blood.V130.Suppl_1.819.819
Published: 2017
Journal Articles

Hematopoietic cell transplantation and HIV cure: where we are and what next?

Shimian Zou, Simone Glynn, Daniel Kuritzkes, Monica Shah, Nakela Cook, Nancy Berliner
Journal: Blood
Blood (2013) 122 (18): 3111–3115.
https://doi.org/10.1182/blood-2013-07-518316
Published: 2013